The M4K Pharma community welcomes the posting of research outputs from collaborators working on the M4K Pharma open science initiative to develop an ALK2 inhibitor for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG).

Submissions must meet the following criteria:

• Scope: Contributions must directly relate to M4K Pharma’s open science ALK2 inhibitor project. This includes datasets, preclinical study reports, experimental protocols, synthetic methods, biological assays, publications, and software tools arising from or supporting this initiative.
• Eligibility: Submissions are open to researchers and collaborators directly involved in the M4K Pharma ALK2 program.
• Quality and Licensing: Submitted materials should be complete, scientifically sound, and made openly available, preferably under a Creative Commons license (e.g., CC BY 4.0), ensuring reuse and broad dissemination. Certain datasets and study reports may be made available under terms that authorize research use but prohibit use in regulatory submissions or commercial applications.
• Moderation: All uploads will be reviewed for relevance to the M4K ALK2 inhibitor project and compliance with open science practices. Submissions may be rejected if they fall outside the scope, are incomplete, or do not meet minimum quality or licensing expectations.

This community is committed to transparency, collaboration, and maximizing the impact of research efforts to accelerate the development of an effective and affordable ALK2 inhibitor for DIPG.